Phase I trial evaluating concurrent vemurafenib and ipilimumab in patients with advanced BRAF-mutant melanoma

被引：0
|
作者：
Ribas, A. [1 ]
Hodi, F. S. [2 ]
Callahan, M. [3 ]
Chmielowski, B. [4 ]
Lawrence, D. [5 ]
Konto, C. [6 ]
McHenry, M. B. [7 ]
Choong, N. [8 ]
Wolchok, J. [3 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Bristol Myers Squibb Co, Oncol Global Clin Res, Wallingford, CT 06492 USA
[7] Bristol Myers Squibb Co, Global Biometr Sci, Wallingford, CT 06492 USA
[8] Roche, Prod Dev Oncol, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3736
引用
收藏
页码：S867 / S867
页数：1
相关论文
共 50 条
  • [1] Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients ( pts) with BRAF-mutant advanced cancer
    Kato, Shumei
    Janku, Filip
    Piha-Paul, Sarina Anne
    Naing, Aung
    Karp, Daniel D.
    Tsimberidou, Apostolia Maria
    Subbiah, Vivek
    Zinner, Ralph
    Hwu, Wen-Jen
    Javle, Milind M.
    Parkhurst, Kristin L.
    Ramzanali, Nishma M.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Chae, Young Kwang
    Kim, Kevin
    Falchook, Gerald Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study
    Kato, Shumei
    Naing, Aung
    Falchook, Gerald
    Holley, Veronica R.
    Velez-Bravo, Vivianne M.
    Patel, Sapna
    Zinner, Ralph G.
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia M.
    Hong, David S.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Janku, Filip
    [J]. CANCER RESEARCH, 2015, 75
  • [3] Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma
    Diab, Adi
    Martin, Alison
    Simpson, Lauren
    Algazi, Alain Patrick
    Chawla, Purvi
    Kim, Dae Won
    Santra, Sourav
    Patel, Vruti
    Jadhav, Nitin
    Abhyankar, Dhiraj
    Davies, Michael A.
    Buch, Shama C.
    Kim, Kevin
    Daud, Adil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] VemurafenibResistance to vemurafenib in BRAF-mutant metastatic melanoma: case report
    [J]. Reactions Weekly, 2015, 1533 (1) : 437 - 437
  • [5] Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
    Harding, James J.
    Catalanotti, Federica
    Yaqubie, Amin
    McDermott, Gregory C.
    Kersellius, Romona
    Merghoub, Taha
    Carvajal, Richard D.
    D'Angelo, Sandra P.
    Dickson, Mark Andrew
    Schwartz, Gary K.
    Wolchok, Jedd D.
    Berger, Michael F.
    Solit, David B.
    Chapman, Paul B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
    Jang, S.
    Atkins, M. B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (01) : 24 - 31
  • [7] Management of a Patient With Advanced BRAF-Mutant Melanoma
    Ashworth, Michelle T.
    Daud, Adil
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (03): : 315 - 319
  • [8] The perspectives and challenges in BRAF-mutant advanced melanoma
    Romanova, Alexandra
    Balandina, Anastasiia
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 45 - 45
  • [9] Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.
    Bai, Xue
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Cui, Chuanliang
    Kong, Yan
    Dai, Jie
    Mao, Li Li
    Wang, Xuan
    Li, Si Ming
    Tang, Bixia
    Lian, Bin
    Zhou, Li
    Yan, Xieqiao
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
    Harding, James J.
    Catalanotti, Federica
    Munhoz, Rodrigo R.
    Cheng, Donavan T.
    Yaqubie, Amin
    Kelly, Nicole
    Mcdermott, Gregory C.
    Kersellius, Romona
    Merghoub, Taha
    Lacouture, Mario E.
    Carvajal, Richard D.
    Panageas, Katherine S.
    Berger, Michael F.
    Rosen, Neal
    Solit, David B.
    Chapman, Paul B.
    [J]. ONCOLOGIST, 2015, 20 (07): : 789 - 797
12345